EUVIMED · CrossrefJournal
Cancer Immunology, Immunotherapy
ISSN 0340-7004 · Springer Science and Business Media LLC
Latest articles
Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3
CD204-positive M2-like tumor-associated macrophages increase migration of gastric cancer cells by upregulating miR-210 to reduce NTN4 expression
Development of a cellular model to study CCR8 signaling in tumor-infiltrating regulatory T cells
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion
XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models
Apolipoprotein C-III itself stimulates the Syk/cPLA2-induced inflammasome activation of macrophage to boost anti-tumor activity of CD8+ T cell
PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study
Human anaerobic microbiome: a promising and innovative tool in cancer prevention and treatment by targeting pyruvate metabolism
The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients
Cholesterol induction in CD8+ T cell exhaustion in colorectal cancer via the regulation of endoplasmic reticulum-mitochondria contact sites
The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression
Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome
Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer
Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic model
The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma
Organ-on-a-chip models for development of cancer immunotherapies
Spatial immune composition of tumor microenvironment in patients with pancreatic cancer
Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer
Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
Chimeric antigen receptor macrophages activated through TLR4 or IFN-γ receptors suppress breast cancer growth by targeting VEGFR2
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment
Murine regulatory T cells utilize granzyme B to promote tumor metastasis
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
Volumes
2026 · 32024 · 202023 · 3522022 · 2482021 · 3132020 · 2312019 · 1832018 · 1812017 · 1512016 · 1422015 · 1522014 · 1232013 · 1672012 · 2302011 · 1702010 · 1892009 · 1952008 · 1702007 · 1612006 · 2052005 · 1262004 · 1352003 · 972002 · 942001 · 832000 · 871999 · 831998 · 881997 · 1111996 · 971995 · 2111994 · 2371993 · 1221992 · 1031991 · 1221990 · 1111989 · 1461988 · 911987 · 931986 · 119
EUVIMED